Literature DB >> 17577681

Polymorphism C3435T of the MDR1 gene in Central Americans and Spaniards.

J Vicente1, Blanca Sinues, A Fanlo, P Vasquez, J C Medina, B Martinez-Jarreta.   

Abstract

The human multidrug resistance gene (MDR1) encodes for P-glycoprotein (P-gp) which is a transmembrane transporter protein that acts as an efflux pump for a number of lypophilic compounds. It plays a protective role for cells against DNA damage. The wobble C3435T polymorphism at exon 26 has been associated with different expression levels and activity. Differences in allele frequency of the C3435T polymorphism have been demonstrated between distinct ethnic groups. In our study we examined these polymorphisms in 433 healthy individuals. From these, 229 were Central American mestizos from Nicaragua (n = 117) and El Salvador (n = 112) to be compared with a group of 204 North Spaniards, with the aim of detecting potential genotypic differences between these populations. The genotypes were determined by PCR-RFLP. The frequencies of the C allele were very similar among Central Americans (0.53) and Spaniards (0.52), which is consistent with the ethnic origin of Central American individuals (Amerindians and European Caucasians). In comparison to other previously studied populations, the C allele frequency in Central Americans was significantly lower than that found in African populations and higher than that observed in the Indian and Southwest Asian populations. These data may be relevant for dose recommendation of P-gp substrate drugs and also for studies of allele disease association in the Central American population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17577681     DOI: 10.1007/s11033-007-9109-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  41 in total

1.  North African genes in Iberia studied by Y-chromosome DNA haplotype 5.

Authors:  G Lucotte; N Gérard; G Mercier
Journal:  Hum Biol       Date:  2001-10       Impact factor: 0.553

2.  Distribution of the functional MDR1 C3435T polymorphism in the Han population of China.

Authors:  Yanhong Li; Yonghua Wang; Jie Sun; Yan Li; Ling Yang
Journal:  Swiss Med Wkly       Date:  2006-06-10       Impact factor: 2.193

3.  The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.

Authors:  R Kerb; A S Aynacioglu; J Brockmöller; R Schlagenhaufer; S Bauer; T Szekeres; A Hamwi; M Fritzer-Szekeres; C Baumgartner; H Z Ongen; P Güzelbey; I Roots; U Brinkmann
Journal:  Pharmacogenomics J       Date:  2001       Impact factor: 3.550

4.  Polymorphic Alu insertions and the Asian origin of Native American populations.

Authors:  G E Novick; C C Novick; J Yunis; E Yunis; P Antunez de Mayolo; W D Scheer; P L Deininger; M Stoneking; D S York; M A Batzer; R J Herrera
Journal:  Hum Biol       Date:  1998-02       Impact factor: 0.553

Review 5.  Population genetics, history, and health patterns in native americans.

Authors:  Connie J Mulligan; Keith Hunley; Suzanne Cole; Jeffrey C Long
Journal:  Annu Rev Genomics Hum Genet       Date:  2004       Impact factor: 8.929

Review 6.  Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs.

Authors:  Toshiyuki Sakaeda; Tsutomu Nakamura; Katsuhiko Okumura
Journal:  Pharmacogenomics       Date:  2003-07       Impact factor: 2.533

7.  MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients.

Authors:  Thomas Illmer; Ulrich S Schuler; Christian Thiede; Ute I Schwarz; Richard B Kim; Sebastian Gotthard; Daniel Freund; Ulrike Schäkel; Gerhard Ehninger; Markus Schaich
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

Review 8.  Clinical aspects of the MDR1 (ABCB1) gene polymorphism.

Authors:  Michel Eichelbaum; Martin F Fromm; Matthias Schwab
Journal:  Ther Drug Monit       Date:  2004-04       Impact factor: 3.681

9.  Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease.

Authors:  Taku Furuno; Maria-Teresa Landi; Mauro Ceroni; Neil Caporaso; Ilaria Bernucci; Giuseppe Nappi; Emilia Martignoni; Elke Schaeffeler; Michel Eichelbaum; Matthias Schwab; Ulrich M Zanger
Journal:  Pharmacogenetics       Date:  2002-10

Review 10.  Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance.

Authors:  Catia Marzolini; Erik Paus; Thierry Buclin; Richard B Kim
Journal:  Clin Pharmacol Ther       Date:  2004-01       Impact factor: 6.875

View more
  4 in total

1.  Inter and intra-ethnic differences in the distribution of the molecular variants of TPMT, UGT1A1 and MDR1 genes in the South Indian population.

Authors:  Gurusamy Umamaheswaran; Dhakchinamoorthi Krishna Kumar; Dhandapani Kayathiri; Subramanian Rajan; Deepak Gopal Shewade; Steven Aibor Dkhar; Sajjanavar Manjunath; Prayaga Ushakiran; Gangadharan Reneega; Kukreti Ritushree; Chandrasekaran Adithan
Journal:  Mol Biol Rep       Date:  2012-02-09       Impact factor: 2.316

Review 2.  Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.

Authors:  Carolina Céspedes-Garro; María-Eugenia G Naranjo; Fernanda Rodrigues-Soares; Adrián LLerena; Jorge Duconge; Lazara K Montané-Jaime; Hilda Roblejo; Humberto Fariñas; María de Los A Campos; Ronald Ramírez; Víctor Serrano; Carmen I Villagrán; Eva M Peñas-LLedó
Journal:  Pharmacogenomics       Date:  2016-09-16       Impact factor: 2.533

3.  Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.

Authors:  Omar Janneh; Patrick G Bray; Elizabeth Jones; Christoph Wyen; Peter Chiba; David J Back; Saye H Khoo
Journal:  J Antimicrob Chemother       Date:  2010-03-17       Impact factor: 5.790

4.  ABCB1 single nucleotide polymorphisms in the Brazilian population.

Authors:  Marcos Antonio Mauricio Scheiner; Arthur Motta Damasceno; Raquel Ciuvalschi Maia
Journal:  Mol Biol Rep       Date:  2009-05-13       Impact factor: 2.316

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.